SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
GAITHERSBURG, Md., Feb. 20, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017.
Conference call details are as follows:
| Date: | Monday, February 27, 2017 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” | |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, February 27, 2017, until midnight March 3, 2017 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until April 30, 2017 | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
